DE69910831D1 - Epothilonderivate und ihre verwendung als antitumormittel - Google Patents
Epothilonderivate und ihre verwendung als antitumormittelInfo
- Publication number
- DE69910831D1 DE69910831D1 DE69910831T DE69910831T DE69910831D1 DE 69910831 D1 DE69910831 D1 DE 69910831D1 DE 69910831 T DE69910831 T DE 69910831T DE 69910831 T DE69910831 T DE 69910831T DE 69910831 D1 DE69910831 D1 DE 69910831D1
- Authority
- DE
- Germany
- Prior art keywords
- epothilone derivatives
- antituary
- agents
- antituary agents
- epothilone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH253098 | 1998-12-22 | ||
| CH253098 | 1998-12-22 | ||
| PCT/EP1999/010129 WO2000037473A1 (en) | 1998-12-22 | 1999-12-20 | Epothilone derivatives and their use as antitumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69910831D1 true DE69910831D1 (de) | 2003-10-02 |
| DE69910831T2 DE69910831T2 (de) | 2004-07-15 |
Family
ID=4235876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69910831T Expired - Lifetime DE69910831T2 (de) | 1998-12-22 | 1999-12-20 | Epothilonderivate und ihre verwendung als antitumormittel |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6387927B1 (de) |
| EP (1) | EP1140944B1 (de) |
| JP (1) | JP2002533346A (de) |
| CN (1) | CN1122668C (de) |
| AT (1) | ATE248175T1 (de) |
| AU (1) | AU2795000A (de) |
| BR (1) | BR9916833A (de) |
| CA (1) | CA2352505C (de) |
| DE (1) | DE69910831T2 (de) |
| ES (1) | ES2207983T3 (de) |
| PT (1) | PT1140944E (de) |
| WO (1) | WO2000037473A1 (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2206607T3 (es) | 1995-11-17 | 2004-05-16 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Derivados de epotilones, preparacion y utilizacion. |
| DE59712968D1 (de) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilone E und F |
| US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
| US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
| WO2001092255A2 (en) * | 2000-05-26 | 2001-12-06 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| US20020128213A1 (en) * | 2000-09-25 | 2002-09-12 | Leonard Katz | Sixteen-membered macrolide compounds |
| NZ526871A (en) * | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| SK288098B6 (sk) | 2001-01-25 | 2013-07-02 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
| KR20030071853A (ko) | 2001-01-25 | 2003-09-06 | 브리스톨-마이어스스퀴브컴파니 | 에포틸론 유사체를 함유한 비경구용 제제 |
| RU2003128311A (ru) | 2001-02-20 | 2005-03-10 | Бристол-Маерс Сквибб Компани (Us) | Способ лечения резистентных опухолей с применением аналогов эпотилона |
| EE200300397A (et) | 2001-02-20 | 2003-12-15 | Bristol-Myers Squibb Company | Epotilooni derivaadid refraktaarsete kasvajate raviks |
| WO2002072085A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| MXPA03010909A (es) | 2001-06-01 | 2004-02-17 | Bristol Myers Squibb Co | Derivados de epotilona. |
| EP1435353A4 (de) * | 2001-10-03 | 2006-01-04 | Nippon Soda Co | Neue heterocyclische verbindung und entzündungshemmendes mittel |
| IL162595A0 (en) * | 2002-01-14 | 2005-11-20 | Novartis Ag | Combinations comprising epothilones and antimetabolites |
| TW200303202A (en) * | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
| US6719540B2 (en) | 2002-03-12 | 2004-04-13 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
| WO2003077903A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| AU2003243561A1 (en) | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| WO2004018478A2 (en) | 2002-08-23 | 2004-03-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| TWI344468B (en) | 2002-09-04 | 2011-07-01 | Schering Corp | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| WO2004026254A2 (en) | 2002-09-23 | 2004-04-01 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
| AU2003296908A1 (en) * | 2002-09-27 | 2004-05-04 | Nereus Pharmaceuticals, Inc. | Macrocyclic lactams |
| DE10256982A1 (de) * | 2002-12-05 | 2004-06-24 | Schering Ag | Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung |
| US20040146632A1 (en) * | 2003-01-23 | 2004-07-29 | Cristina Sayman | Effective multi-component penetrating and flavoring marinade |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| GB0405898D0 (en) * | 2004-03-16 | 2004-04-21 | Novartis Ag | Organic compounds |
| US7122700B2 (en) * | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
| EP1640004A1 (de) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Verwendung von Epothilonen zur Behandlung von Knochenmetastasen und Knochentumoren oder Knochenkrebs |
| EP1674098A1 (de) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit |
| US7754850B2 (en) | 2005-02-11 | 2010-07-13 | University Of Southern California | Chimeric disintegrin domain |
| WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| EP1845096A1 (de) * | 2006-03-27 | 2007-10-17 | ETH Zürich | 12-Aza-epothilones, Verfahren zu deren Herstellung und deren Vewendung als Antiproliferative Mittel |
| WO2007130501A2 (en) * | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
| US8163792B2 (en) | 2006-05-16 | 2012-04-24 | Pharmascience Inc. | IAP BIR domain binding compounds |
| DE102007016046A1 (de) | 2007-03-30 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung |
| EP2065054A1 (de) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Kombinationen mit einem Prostaglandin und Verwendungen davon |
| EP2070521A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Nanopartikel mit modifizierter Oberfläche |
| DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
| CN101519404B (zh) * | 2008-02-29 | 2016-01-20 | 唐莉 | 15环噻酮衍生物及其制备方法与应用 |
| US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
| EP2210584A1 (de) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stabile Polymerzusammensetzung mit einem Epothilon und einem amphiphilischen Blockpolymer |
| ES2625637T3 (es) | 2010-02-12 | 2017-07-20 | Pharmascience Inc. | Compuestos de unión al dominio BIR IAP |
| CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| WO2013092983A2 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
| EP3564259A3 (de) | 2012-11-09 | 2020-02-12 | Innate Pharma | Kennungen für tgase-vermittelte konjugation |
| EP2968582B1 (de) | 2013-03-15 | 2020-07-01 | Innate Pharma | Festphasen-tgase-vermittelte konjugation von antikörpern |
| US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
| JP6744212B2 (ja) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU756699B2 (en) * | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
-
1999
- 1999-12-20 PT PT99969216T patent/PT1140944E/pt unknown
- 1999-12-20 WO PCT/EP1999/010129 patent/WO2000037473A1/en active IP Right Grant
- 1999-12-20 EP EP99969216A patent/EP1140944B1/de not_active Expired - Lifetime
- 1999-12-20 AU AU27950/00A patent/AU2795000A/en not_active Abandoned
- 1999-12-20 AT AT99969216T patent/ATE248175T1/de not_active IP Right Cessation
- 1999-12-20 ES ES99969216T patent/ES2207983T3/es not_active Expired - Lifetime
- 1999-12-20 CN CN99815116A patent/CN1122668C/zh not_active Expired - Fee Related
- 1999-12-20 CA CA002352505A patent/CA2352505C/en not_active Expired - Fee Related
- 1999-12-20 BR BR9916833-2A patent/BR9916833A/pt not_active Application Discontinuation
- 1999-12-20 DE DE69910831T patent/DE69910831T2/de not_active Expired - Lifetime
- 1999-12-20 JP JP2000589543A patent/JP2002533346A/ja active Pending
-
2001
- 2001-06-01 US US09/871,860 patent/US6387927B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6387927B1 (en) | 2002-05-14 |
| CN1122668C (zh) | 2003-10-01 |
| CN1332742A (zh) | 2002-01-23 |
| CA2352505C (en) | 2009-04-07 |
| EP1140944A1 (de) | 2001-10-10 |
| AU2795000A (en) | 2000-07-12 |
| EP1140944B1 (de) | 2003-08-27 |
| ATE248175T1 (de) | 2003-09-15 |
| CA2352505A1 (en) | 2000-06-29 |
| PT1140944E (pt) | 2004-01-30 |
| WO2000037473A1 (en) | 2000-06-29 |
| BR9916833A (pt) | 2001-09-25 |
| DE69910831T2 (de) | 2004-07-15 |
| ES2207983T3 (es) | 2004-06-01 |
| JP2002533346A (ja) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69910831D1 (de) | Epothilonderivate und ihre verwendung als antitumormittel | |
| DK1070056T3 (da) | Phthalazinon-PDE III/IV-inhibitorer | |
| BR0207278A (pt) | Derivados de ftalazinona-piperidina como inibidores de pde4 | |
| ATE227277T1 (de) | Isoxazoline derivate und ihre verwendung als antimikroben | |
| PT998460E (pt) | Novos derivados de tetrazole | |
| BR0209149A (pt) | Ftalazinonas | |
| DK1042319T3 (da) | Dihydrobenzofuraner | |
| TR200201128T2 (tr) | PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri. | |
| DE50201565D1 (de) | 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie | |
| AP2001002188A0 (en) | 5HT1 antagonists for antidepressant therapy. | |
| ATE259813T1 (de) | Triazolopyrimidinderivate | |
| DK1377574T3 (da) | 6-phenylbenzonaphtyridiner | |
| EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
| DE50010403D1 (de) | Polycyclische thiazol-systeme und ihre verwendung als anorektika | |
| ATE508130T1 (de) | 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren | |
| ATE213236T1 (de) | Substituierte benzyloxyimino-verbindungen | |
| ATE218138T1 (de) | N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung | |
| ATE374778T1 (de) | Organosiliziumverbindungen und deren verwendung | |
| ATE340175T1 (de) | Imidazo(4,5-böchinolinderivate und ihre verwendung als inhibitoren der induzierbaren no- synthase | |
| DE60311000D1 (de) | Indolderivate und deren verwendung als 5-ht liganden | |
| DE60200935D1 (de) | Diazocinderivate und deren verwendung als tryptase inhibitoren | |
| ATE263139T1 (de) | 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie | |
| ATE305298T1 (de) | 4,5-dihydro-2-thiazolylaminderivate und ihre verwendung als no-synthase inhibitoren | |
| ATE239015T1 (de) | N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |